Back to News
Market Impact: 0.38
GSK strikes up to $750 million deal for cancer-targeting drug
Source: reuters.com
M&A & RestructuringHealthcare & BiotechPrivate Markets & Venture
GSK agreed to acquire a trispecific T-cell engager cancer drug from China-based Chimagen Biosciences in a deal worth up to $750 million. The transaction expands GSK's oncology pipeline through an immunotherapy designed to help T-cells target cancer, though deal terms beyond the maximum value were not disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
GSK0.62
More News
- GSK shares rise as Berenberg upgrades to Buy on stronger drug pipeline
- Grab aims for 'next level' in financial services with purchase of buy-now pay-later platform Atome
- BlackRock’s Fink, Blackstone’s Gray Back Carney’s Canada Investment Push
- Exclusive-Malaysia talks to rival airlines as it monitors AirAsia’s financial health, sources say
- Factbox-Private equity, foreign investors fuel Aussie M&A activity in 2026
- Australia’s Reliance Worldwide agrees to Brookfield’s $2.9 billion buyout bid
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How the 2026 Milan-Cortina Winter Olympics Will Reshape Company Revenues and Stock Performance
- Can Hedge Funds Use ChatGPT? A Control Framework